Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2007

Open Access 01-12-2007 | Review

Cytopathic Mechanisms of HIV-1

Author: Joshua M Costin

Published in: Virology Journal | Issue 1/2007

Login to get access

Abstract

The human immunodeficiency virus type 1 (HIV-1) has been intensely investigated since its discovery in 1983 as the cause of acquired immune deficiency syndrome (AIDS). With relatively few proteins made by the virus, it is able to accomplish many tasks, with each protein serving multiple functions. The Envelope glycoprotein, composed of the two noncovalently linked subunits, SU (surface glycoprotein) and TM (transmembrane glycoprotein) is largely responsible for host cell recognition and entry respectively. While the roles of the N-terminal residues of TM is well established as a fusion pore and anchor for Env into cell membranes, the role of the C-terminus of the protein is not well understood and is fiercely debated. This review gathers information on TM in an attempt to shed some light on the functional regions of this protein.
Appendix
Available only for authorised users
Literature
1.
Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A: Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981, 305: 1425-1431.PubMed
2.
Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA, Holzman RS, Wormser G, Brettman L, Lange M, Murray HW, Cunningham-Rundles S: An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981, 305: 1431-1438.PubMed
3.
Gallo RC, Montagnier L: Historical essay. Prospects for the future. Science 2002, 298: 1730-1731. 10.1126/science.1079864PubMed
4.
Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, et al.: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220: 868-871. 10.1126/science.6189183PubMed
5.
Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker TJ, Redfield R, Oleske J, Safai B, et al.: Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984, 224: 500-503. 10.1126/science.6200936PubMed
6.
Gallo RC, Montagnier L: The discovery of HIV as the cause of AIDS. N Engl J Med 2003, 349: 2283-2285. 10.1056/NEJMp038194PubMed
7.
Montagnier L: Historical essay. A history of HIV discovery. Science 2002, 298: 1727-1728. 10.1126/science.1079027PubMed
8.
Gallo RC: Historical essay. The early years of HIV/AIDS. Science 2002, 298: 1728-1730. 10.1126/science.1078050PubMed
9.
Levy JA, Hoffman AD, Kramer SM, Landis JA, Shimabukuro JM, Oshiro LS: Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984, 225: 840-842. 10.1126/science.6206563PubMed
10.
11.
Daar ES, Moudgil T, Meyer RD, Ho DD: Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991, 324: 961-964.PubMed
12.
Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261: 1179-1181. 10.1126/science.8356453PubMed
13.
Coffin JM: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267: 483-489. 10.1126/science.7824947PubMed
14.
Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373: 123-126. 10.1038/373123a0PubMed
15.
Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373: 117-122. 10.1038/373117a0PubMed
16.
Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271: 1582-1586. 10.1126/science.271.5255.1582PubMed
17.
Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD: High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259: 1749-1754. 10.1126/science.8096089PubMed
18.
Fahey JL, Taylor JM, Manna B, Nishanian P, Aziz N, Giorgi JV, Detels R: Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. Aids 1998, 12: 1581-1590. 10.1097/00002030-199813000-00004PubMed
19.
Arnaout RA, Lloyd AL, O'Brien TR, Goedert JJ, Leonard JM, Nowak MA: A simple relationship between viral load and survival time in HIV-1 infection. Proc Natl Acad Sci USA 1999, 96: 11549-11553. 10.1073/pnas.96.20.11549PubMedPubMedCentral
20.
Garry RF: Potential mechanisms for the cytopathic properties of HIV. Aids 1989, 3: 683-694.PubMed
21.
Strebel K, Klimkait T, Martin MA: A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 1988, 241: 1221-1223. 10.1126/science.3261888PubMed
22.
Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381: 661-666. 10.1038/381661a0PubMed
23.
Saez-Cirion A, Nieva JL, Gallaher WR: The hydrophobic internal region of bovine prion protein shares structural and functional properties with HIV type 1 fusion peptide. AIDS Res Hum Retroviruses 2003, 19: 969-978. 10.1089/088922203322588323PubMed
24.
Wyma DJ, Kotov A, Aiken C: Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles. J Virol 2000, 74: 9381-9387. 10.1128/JVI.74.20.9381-9387.2000PubMedPubMedCentral
25.
Pugliese A, Vidotto V, Beltramo T, Petrini S, Torre D: A review of HIV-1 Tat protein biological effects. Cell Biochem Funct 2004.
26.
Strebel K: Virus-host interactions: role of HIV proteins Vif, Tat, and Rev. Aids 2003,17(Suppl 4):S25-34. 10.1097/00002030-200317004-00003PubMed
27.
Montal M: Structure-function correlates of Vpu, a membrane protein of HIV-1. FEBS Lett 2003, 552: 47-53. 10.1016/S0014-5793(03)00849-4PubMed
28.
Doms RW, Trono D: The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 2000, 14: 2677-2688. 10.1101/gad.833300PubMed
29.
Werner T, Ferroni S, Saermark T, Brack-Werner R, Banati RB, Mager R, Steinaa L, Kreutzberg GW, Erfle V: HIV-1 Nef protein exhibits structural and functional similarity to scorpion peptides interacting with K+ channels. Aids 1991, 5: 1301-1308. 10.1097/00002030-199111000-00003PubMed
30.
Sherman MP, de Noronha CM, Heusch MI, Greene S, Greene WC: Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr. J Virol 2001, 75: 1522-1532. 10.1128/JVI.75.3.1522-1532.2001PubMedPubMedCentral
31.
Piller SC, Ewart GD, Premkumar A, Cox GB, Gage PW: Vpr protein of human immunodeficiency virus type 1 forms cation-selective channels in planar lipid bilayers. Proc Natl Acad Sci USA 1996, 93: 111-115. 10.1073/pnas.93.1.111PubMedPubMedCentral
32.
Boya P, Pauleau AL, Poncet D, Gonzalez-Polo RA, Zamzami N, Kroemer G: Viral proteins targeting mitochondria: controlling cell death. Biochim Biophys Acta 2004, 1659: 178-189. 10.1016/j.bbabio.2004.08.007PubMed
33.
Basanez G, Zimmerberg J: HIV and apoptosis death and the mitochondrion. J Exp Med 2001, 193: F11-14. 10.1084/jem.193.4.F11PubMedPubMedCentral
34.
Halestrap AP, Brennerb C: The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. Curr Med Chem 2003, 10: 1507-1525. 10.2174/0929867033457278PubMed
35.
Sherman MP, De Noronha CM, Williams SA, Greene WC: Insights into the biology of HIV-1 viral protein R. DNA Cell Biol 2002, 21: 679-688. 10.1089/104454902760330228PubMed
36.
Rasheed S, Gottlieb AA, Garry RF: Cell killing by ultraviolet-inactivated human immunodeficiency virus. Virology 1986, 154: 395-400. 10.1016/0042-6822(86)90465-4PubMed
37.
Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, et al.: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100: 587-597. 10.1016/S0092-8674(00)80694-7PubMed
38.
Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47: 333-348. 10.1016/0092-8674(86)90590-8PubMed
39.
Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 1996, 2: 1244-1247. 10.1038/nm1196-1244PubMed
40.
Wahl SM, Greenwell-Wild T, Peng G, Ma G, Orenstein JM, Vazquez N: Viral and host cofactors facilitate HIV-1 replication in macrophages. J Leukoc Biol 2003, 74: 726-735. 10.1189/jlb.0503220PubMed
41.
Philpott SM: HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res 2003, 1: 217-227. 10.2174/1570162033485357PubMed
42.
Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86: 367-377. 10.1016/S0092-8674(00)80110-5PubMed
43.
Miedema F, Meyaard L, Koot M, Klein MR, Roos MT, Groenink M, Fouchier RA, Van't Wout AB, Tersmette M, Schellekens PT, et al.: Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev 1994, 140: 35-72. 10.1111/j.1600-065X.1994.tb00864.xPubMed
44.
Holm GH, Zhang C, Gorry PR, Peden K, Schols D, De Clercq E, Gabuzda D: Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure. J Virol 2004, 78: 4541-4551. 10.1128/JVI.78.9.4541-4551.2004PubMedPubMedCentral
45.
Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997, 94: 1925-1930. 10.1073/pnas.94.5.1925PubMedPubMedCentral
46.
Alimonti JB, Ball TB, Fowke KR: Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 2003, 84: 1649-1661. 10.1099/vir.0.19110-0PubMed
47.
Douek DC: Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev 2003, 5: 172-177.PubMed
48.
McMichael AJ, Ogg G, Wilson J, Callan M, Hambleton S, Appay V, Kelleher T, Rowland-Jones S: Memory CD8+ T cells in HIV infection. Philos Trans R Soc Lond B Biol Sci 2000, 355: 363-367. 10.1098/rstb.2000.0575PubMedPubMedCentral
49.
Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312: 763-767. 10.1038/312763a0PubMed
50.
Simon V, Ho DD: HIV-1 dynamics in vivo: implications for therapy. Nat Rev Microbiol 2003, 1: 181-190. 10.1038/nrmicro772PubMed
51.
McLean AR, Michie CA: In vivo estimates of division and death rates of human T lymphocytes. Proc Natl Acad Sci USA 1995, 92: 3707-3711. 10.1073/pnas.92.9.3707PubMedPubMedCentral
52.
Lawn SD, Butera ST, Folks TM: Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001, 14: 753-777. table of contents. 10.1128/CMR.14.4.753-777.2001PubMedPubMedCentral
53.
Mohri H, Bonhoeffer S, Monard S, Perelson AS, Ho DD: Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science 1998, 279: 1223-1227. 10.1126/science.279.5354.1223PubMed
54.
Cloyd MW, Lynn WS: Perturbation of host-cell membrane is a primary mechanism of HIV cytopathology. Virology 1991, 181: 500-511. 10.1016/0042-6822(91)90882-CPubMed
55.
Takeya M, Naito M, Eto K, Takahashi K: Immunohistochemical characterization of multinucleated giant cells in the brain of a Japanese AIDS patient. Acta Pathol Jpn 1991, 41: 212-216.PubMed
56.
Vago L, Castagna A, Lazzarin A, Trabattoni G, Cinque P, Costanzi G: Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. J Acquir Immune Defic Syndr 1993, 6: 42-45.PubMed
57.
Somasundaran M, Robinson HL: A major mechanism of human immunodeficiency virus-induced cell killing does not involve cell fusion. J Virol 1987, 61: 3114-3119.PubMedPubMedCentral
58.
Micklem KJ, Pasternak CA: Surface components involved in virally mediated membrane changes. Biochem J 1977, 162: 405-410.PubMedPubMedCentral
59.
Impraim CC, Foster KA, Micklem KJ, Pasternak CA: Nature of virally mediated changes in membrane permeability to small molecules. Biochem J 1980, 186: 847-860.PubMedPubMedCentral
60.
Foster KA, Gill K, Micklem KJ, Pasternak CA: Survey of virally mediated permeability changes. Biochem J 1980, 190: 639-646.PubMedPubMedCentral
61.
Bashford CL, Alder GM, Patel K, Pasternak CA: Common action of certain viruses, toxins, and activated complement: pore formation and its prevention by extracellular Ca2+. Biosci Rep 1984, 4: 797-805. 10.1007/BF01128822PubMed
62.
Grewe C, Beck A, Gelderblom HR: HIV: early virus-cell interactions. J Acquir Immune Defic Syndr 1990, 3: 965-974.PubMed
63.
Carrasco L: Modification of membrane permeability by animal viruses. Adv Virus Res 1995, 45: 61-112.PubMed
64.
Gonzalez ME, Carrasco L: Viroporins. FEBS Lett 2003, 552: 28-34. 10.1016/S0014-5793(03)00780-4PubMed
65.
Choi B, Gatti PJ, Haislip AM, Fermin CD, Garry RF: Role of potassium in human immunodeficiency virus production and cytopathic effects. Virology 1998, 247: 189-199. 10.1006/viro.1998.9251PubMed
66.
Voss TG, Fermin CD, Levy JA, Vigh S, Choi B, Garry RF: Alteration of intracellular potassium and sodium concentrations correlates with induction of cytopathic effects by human immunodeficiency virus. J Virol 1996, 70: 5447-5454.PubMedPubMedCentral
67.
Voss TG, Gatti PJ, Fermin CD, Garry RF: Reduction of human immunodeficiency virus production and cytopathic effects by inhibitors of the Na+/K+/2Cl- cotransporter. Virology 1996, 219: 291-294. 10.1006/viro.1996.0249PubMed
68.
Makutonina A, Voss TG, Plymale DR, Fermin CD, Norris CH, Vigh S, Garry RF: Human immunodeficiency virus infection of T-lymphoblastoid cells reduces intracellular pH. J Virol 1996, 70: 7049-7055.PubMedPubMedCentral
69.
Garry RF, Bishop JM, Parker S, Westbrook K, Lewis G, Waite MR: Na+ and K+ concentrations and the regulation of protein synthesis in Sindbis virus-infected chick cells. Virology 1979, 96: 108-120. 10.1016/0042-6822(79)90177-6PubMed
70.
Garry RF: Sindbis virus-induced inhibition of protein synthesis is partially reversed by medium containing an elevated potassium concentration. J Gen Virol 1994,75(Pt 2):411-415.PubMed
71.
Garry RF, Gottlieb AA, Zuckerman KP, Pace JR, Frank TW, Bostick DA: Cell surface effects of human immunodeficiency virus. Biosci Rep 1988, 8: 35-48. 10.1007/BF01128970PubMed
72.
Garry RF, Westbrook K, Waite MR: Differential effects of ouabain on host- and sindbis virus-specified protein synthesis. Virology 1979, 99: 179-182. 10.1016/0042-6822(79)90051-5PubMed
73.
Castrillo JL, Lopez-Rivas A, Carrasco L: Effects of extracellular cations on translation in poliovirus-infected cells. J Gen Virol 1987,68(Pt 2):325-333.PubMed
74.
Loewy A, Smyth J, von Bonsdorff CH, Liljestrom P, Schlesinger MJ: The 6-kilodalton membrane protein of Semliki Forest virus is involved in the budding process. J Virol 1995, 69: 469-475.PubMedPubMedCentral
75.
Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM: The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 1990, 64: 621-629.PubMedPubMedCentral
76.
Zebedee SL, Lamb RA: Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62: 2762-2772.PubMedPubMedCentral
77.
Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH: The molecular basis of the specific anti-influenza action of amantadine. Embo J 1985, 4: 3021-3024.PubMedPubMedCentral
78.
Wang C, Lamb RA, Pinto LH: Direct measurement of the influenza A virus M2 protein ion channel activity in mammalian cells. Virology 1994, 205: 133-140. 10.1006/viro.1994.1628PubMed
79.
Helenius A: Unpacking the incoming influenza virus. Cell 1992, 69: 577-578. 10.1016/0092-8674(92)90219-3PubMed
80.
Bui M, Whittaker G, Helenius A: Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol 1996, 70: 8391-8401.PubMedPubMedCentral
81.
Sugrue RJ, Hay AJ: Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991, 180: 617-624. 10.1016/0042-6822(91)90075-MPubMed
82.
Takeda M, Pekosz A, Shuck K, Pinto LH, Lamb RA: Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 2002, 76: 1391-1399.PubMedPubMedCentral
83.
Holsinger LJ, Nichani D, Pinto LH, Lamb RA: Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol 1994, 68: 1551-1563.PubMedPubMedCentral
84.
Pinto LH, Holsinger LJ, Lamb RA: Influenza virus M2 protein has ion channel activity. Cell 1992, 69: 517-528. 10.1016/0092-8674(92)90452-IPubMed
85.
Mould JA, Drury JE, Frings SM, Kaupp UB, Pekosz A, Lamb RA, Pinto LH: Permeation and activation of the M2 ion channel of influenza A virus. J Biol Chem 2000, 275: 31038-31050. 10.1074/jbc.M003663200PubMed
86.
Duff KC, Ashley RH: The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. Virology 1992, 190: 485-489. 10.1016/0042-6822(92)91239-QPubMed
87.
Tosteson MT, Pinto LH, Holsinger LJ, Lamb RA: Reconstitution of the influenza virus M2 ion channel in lipid bilayers. J Membr Biol 1994, 142: 117-126.PubMed
88.
Watanabe T, Watanabe S, Neumann G, Kida H, Kawaoka Y: Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J Virol 2002, 76: 767-773. 10.1128/JVI.76.2.767-773.2002PubMedPubMedCentral
89.
Fischer WB, Pitkeathly M, Wallace BA, Forrest LR, Smith GR, Sansom MS: Transmembrane peptide NB of influenza B: a simulation, structure, and conductance study. Biochemistry 2000, 39: 12708-12716. 10.1021/bi001000ePubMed
90.
Fischer WB, Forrest LR, Smith GR, Sansom MS: Transmembrane domains of viral ion channel proteins: a molecular dynamics simulation study. Biopolymers 2000, 53: 529-538. 10.1002/(SICI)1097-0282(200006)53:7<529::AID-BIP1>3.0.CO;2-6PubMed
91.
Fischer WB, Pitkeathly M, Sansom MS: Amantadine blocks channel activity of the transmembrane segment of the NB protein from influenza B. Eur Biophys J 2001, 30: 416-420. 10.1007/s002490100157PubMed
92.
Sunstrom NA, Premkumar LS, Premkumar A, Ewart G, Cox GB, Gage PW: Ion channels formed by NB, an influenza B virus protein. J Membr Biol 1996, 150: 127-132. 10.1007/s002329900037PubMed
93.
Mould JA, Paterson RG, Takeda M, Ohigashi Y, Venkataraman P, Lamb RA, Pinto LH: Influenza B virus BM2 protein has ion channel activity that conducts protons across membranes. Dev Cell 2003, 5: 175-184. 10.1016/S1534-5807(03)00190-4PubMed
94.
Premkumar A, Ewart GD, Cox GB, Gage PW: An amino-acid substitution in the influenza-B NB protein affects ion-channel gating. J Membr Biol 2004, 197: 135-143. 10.1007/s00232-004-0648-0PubMed
95.
Hongo S, Sugawara K, Muraki Y, Kitame F, Nakamura K: Characterization of a second protein (CM2) encoded by RNA segment 6 of influenza C virus. J Virol 1997, 71: 2786-2792.PubMedPubMedCentral
96.
Kukol A, Arkin IT: Structure of the influenza C virus CM2 protein transmembrane domain obtained by site-specific infrared dichroism and global molecular dynamics searching. J Biol Chem 2000, 275: 4225-4229. 10.1074/jbc.275.6.4225PubMed
97.
Hongo S, Ishii K, Mori K, Takashita E, Muraki Y, Matsuzaki Y, Sugawara K: Detection of ion channel activity in Xenopus laevis oocytes expressing Influenza C virus CM2 protein. Arch Virol 2004, 149: 35-50. 10.1007/s00705-003-0209-3PubMed
98.
Maldarelli F, Chen MY, Willey RL, Strebel K: Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J Virol 1993, 67: 5056-5061.PubMedPubMedCentral
99.
Strebel K, Klimkait T, Maldarelli F, Martin MA: Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol 1989, 63: 3784-3791.PubMedPubMedCentral
100.
Willey RL, Maldarelli F, Martin MA, Strebel K: Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 1992, 66: 7193-7200.PubMedPubMedCentral
101.
Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V, Thomas D, Strebel K, Benarous R: A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998, 1: 565-574. 10.1016/S1097-2765(00)80056-8PubMed
102.
Ma C, Marassi FM, Jones DH, Straus SK, Bour S, Strebel K, Schubert U, Oblatt-Montal M, Montal M, Opella SJ: Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1. Protein Sci 2002, 11: 546-557. 10.1110/ps.37302PubMedPubMedCentral
103.
Wray V, Federau T, Henklein P, Klabunde S, Kunert O, Schomburg D, Schubert U: Solution structure of the hydrophilic region of HIV-1 encoded virus protein U (Vpu) by CD and 1H NMR spectroscopy. Int J Pept Protein Res 1995, 45: 35-43.PubMed
104.
Fischer WB, Sansom MS: Viral ion channels: structure and function. Biochim Biophys Acta 2002, 1561: 27-45. 10.1016/S0304-4157(01)00009-0PubMed
105.
Schubert U, Bour S, Ferrer-Montiel AV, Montal M, Maldarell F, Strebel K: The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol 1996, 70: 809-819.PubMedPubMedCentral
106.
Ewart GD, Sutherland T, Gage PW, Cox GB: The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J Virol 1996, 70: 7108-7115.PubMedPubMedCentral
107.
Park SH, Mrse AA, Nevzorov AA, Mesleh MF, Oblatt-Montal M, Montal M, Opella SJ: Three-dimensional structure of the channel-forming trans-membrane domain of virus protein "u" (Vpu) from HIV-1. J Mol Biol 2003, 333: 409-424. 10.1016/j.jmb.2003.08.048PubMed
108.
Becker CF, Oblatt-Montal M, Kochendoerfer GG, Montal M: Chemical synthesis and single channel properties of tetrameric and pentameric TASPs (template-assembled synthetic proteins) derived from the transmembrane domain of HIV virus protein u (Vpu). J Biol Chem 2004, 279: 17483-17489. 10.1074/jbc.M313212200PubMed
109.
Coady MJ, Daniel NG, Tiganos E, Allain B, Friborg J, Lapointe JY, Cohen EA: Effects of Vpu expression on Xenopus oocyte membrane conductance. Virology 1998, 244: 39-49. 10.1006/viro.1998.9087PubMed
110.
Tzounopoulos T, Maylie J, Adelman JP: Induction of endogenous channels by high levels of heterologous membrane proteins in Xenopus oocytes. Biophys J 1995, 69: 904-908.PubMedPubMedCentral
111.
Hsu K, Seharaseyon J, Dong P, Bour S, Marban E: Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel. Mol Cell 2004, 14: 259-267. 10.1016/S1097-2765(04)00183-2PubMed
112.
Ulug ET, Garry RF, Bose HR Jr: The role of monovalent cation transport in Sindbis virus maturation and release. Virology 1989, 172: 42-50. 10.1016/0042-6822(89)90105-0PubMed
113.
Ulug ET, Garry RF, Bose HR Jr: Inhibition of Na+K+ATPase activity in membranes of Sindbis virus-infected chick cells. Virology 1996, 216: 299-308. 10.1006/viro.1996.0065PubMed
114.
Welch WJ, Sefton BM: Characterization of a small, nonstructural viral polypeptide present late during infection of BHK cells by Semliki Forest virus. J Virol 1980, 33: 230-237.PubMedPubMedCentral
115.
Sanz MA, Madan V, Carrasco L, Nieva JL: Interfacial domains in Sindbis virus 6 K protein. Detection and functional characterization. J Biol Chem 2003, 278: 2051-2057. 10.1074/jbc.M206611200PubMed
116.
Gonzalez ME, Carrasco L: Human immunodeficiency virus type 1 VPU protein affects Sindbis virus glycoprotein processing and enhances membrane permeabilization. Virology 2001, 279: 201-209. 10.1006/viro.2000.0708PubMed
117.
Sanz MA, Perez L, Carrasco L: Semliki Forest virus 6 K protein modifies membrane permeability after inducible expression in Escherichia coli cells. J Biol Chem 1994, 269: 12106-12110.PubMed
118.
Melton JV, Ewart GD, Weir RC, Board PG, Lee E, Gage PW: Alphavirus 6 K proteins form ion channels. J Biol Chem 2002, 277: 46923-46931. 10.1074/jbc.M207847200PubMed
119.
Wengler G, Koschinski A, Dreyer F: Entry of alphaviruses at the plasma membrane converts the viral surface proteins into an ion-permeable pore that can be detected by electrophysiological analyses of whole-cell membrane currents. J Gen Virol 2003, 84: 173-181. 10.1099/vir.0.18696-0PubMed
120.
Moore LL, Bostick DA, Garry RF: Sindbis virus infection decreases intracellular pH: alkaline medium inhibits processing of Sindbis virus polyproteins. Virology 1988, 166: 1-9. 10.1016/0042-6822(88)90139-0PubMed
121.
Wengler G: In vitro analysis of factors involved in the disassembly of Sindbis virus cores by 60S ribosomal subunits identifies a possible role of low pH. J Gen Virol 2002, 83: 2417-2426.PubMed
122.
Nieva JL, Sanz MA, Carrasco L: Membrane-permeabilizing motif in Semliki forest virus E1 glycoprotein. FEBS Lett 2004, 576: 417-422. 10.1016/j.febslet.2004.09.061PubMed
123.
Carrere-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C, Penin F, Dubuisson J: Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol 2002, 76: 3720-3730. 10.1128/JVI.76.8.3720-3730.2002PubMedPubMedCentral
124.
Harada T, Tautz N, Thiel HJ: E2-p7 region of the bovine viral diarrhea virus polyprotein: processing and functional studies. J Virol 2000, 74: 9498-9506. 10.1128/JVI.74.20.9498-9506.2000PubMedPubMedCentral
125.
Premkumar A, Wilson L, Ewart GD, Gage PW: Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett 2004, 557: 99-103. 10.1016/S0014-5793(03)01453-4PubMed
126.
Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, Harris MP, Rowlands DJ: The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 2003, 535: 34-38. 10.1016/S0014-5793(02)03851-6PubMed
127.
Garry RF, Ulug ET, Bose HR Jr: Membrane-mediated alterations of intracellular Na+ and K+ in lytic-virus-infected and retrovirus-transformed cells. Biosci Rep 1982, 2: 617-623. 10.1007/BF01314226PubMed
128.
Garry RF: Alteration of intracellular monovalent cation concentrations by a poliovirus mutant which encodes a defective 2A protease. Virus Res 1989, 13: 129-141. 10.1016/0168-1702(89)90011-7PubMed
129.
Aldabe R, Barco A, Carrasco L: Membrane permeabilization by poliovirus proteins 2B and 2BC. J Biol Chem 1996, 271: 23134-23137. 10.1074/jbc.271.38.23134PubMed
130.
Agirre A, Barco A, Carrasco L, Nieva JL: Viroporin-mediated membrane permeabilization. Pore formation by nonstructural poliovirus 2B protein. J Biol Chem 2002, 277: 40434-40441. 10.1074/jbc.M205393200PubMed
131.
Cuconati A, Xiang W, Lahser F, Pfister T, Wimmer E: A protein linkage map of the P2 nonstructural proteins of poliovirus. J Virol 1998, 72: 1297-1307.PubMedPubMedCentral
132.
van Kuppeveld FJ, Melchers WJ, Willems PH, Gadella TW Jr: Homomultimerization of the coxsackievirus 2B protein in living cells visualized by fluorescence resonance energy transfer microscopy. J Virol 2002, 76: 9446-9456. 10.1128/JVI.76.18.9446-9456.2002PubMedPubMedCentral
133.
Nieva JL, Agirre A, Nir S, Carrasco L: Mechanisms of membrane permeabilization by picornavirus 2B viroporin. FEBS Lett 2003, 552: 68-73. 10.1016/S0014-5793(03)00852-4PubMed
134.
de Jong AS, Melchers WJ, Glaudemans DH, Willems PH, van Kuppeveld FJ: Mutational analysis of different regions in the coxsackievirus 2B protein: requirements for homo-multimerization, membrane permeabilization, subcellular localization, and virus replication. J Biol Chem 2004, 279: 19924-19935. 10.1074/jbc.M314094200PubMed
135.
de Jong AS, Wessels E, Dijkman HB, Galama JM, Melchers WJ, Willems PH, van Kuppeveld FJ: Determinants for membrane association and permeabilization of the coxsackievirus 2B protein and the identification of the Golgi complex as the target organelle. J Biol Chem 2003, 278: 1012-1021. 10.1074/jbc.M207745200PubMed
136.
Sandoval IV, Carrasco L: Poliovirus infection and expression of the poliovirus protein 2B provoke the disassembly of the Golgi complex, the organelle target for the antipoliovirus drug Ro-090179. J Virol 1997, 71: 4679-4693.PubMedPubMedCentral
137.
Suhy DA, Giddings TH Jr, Kirkegaard K: Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: an autophagy-like origin for virus-induced vesicles. J Virol 2000, 74: 8953-8965. 10.1128/JVI.74.19.8953-8965.2000PubMedPubMedCentral
138.
Van kuppeveld FJ, Melchers WJ, Kirkegaard K, Doedens JR: Structure-function analysis of coxsackie B3 virus protein 2B. Virology 1997, 227: 111-118. 10.1006/viro.1996.8320PubMed
139.
Huang Y, Hogle JM, Chow M: Is the 135S poliovirus particle an intermediate during cell entry? J Virol 2000, 74: 8757-8761. 10.1128/JVI.74.18.8757-8761.2000PubMedPubMedCentral
140.
Tosteson MT, Chow M: Characterization of the ion channels formed by poliovirus in planar lipid membranes. J Virol 1997, 71: 507-511.PubMedPubMedCentral
141.
Tosteson MT, Wang H, Naumov A, Chow M: Poliovirus binding to its receptor in lipid bilayers results in particle-specific, temperature-sensitive channels. J Gen Virol 2004, 85: 1581-1589. 10.1099/vir.0.19745-0PubMed
142.
Danthi P, Tosteson M, Li QH, Chow M: Genome delivery and ion channel properties are altered in VP4 mutants of poliovirus. J Virol 2003, 77: 5266-5274. 10.1128/JVI.77.9.5266-5274.2003PubMedPubMedCentral
143.
Estes MK, Morris AP: A viral enterotoxin. A new mechanism of virus-induced pathogenesis. Adv Exp Med Biol 1999, 473: 73-82.PubMed
144.
Morris AP, Scott JK, Ball JM, Zeng CQ, O'Neal WK, Estes MK: NSP4 elicits age-dependent diarrhea and Ca(2+)mediated I(-) influx into intestinal crypts of CF mice. Am J Physiol 1999, 277: G431-444.PubMed
145.
Morris AP, Estes MK: Microbes and microbial toxins: paradigms for microbial-mucosal interactions. VIII. Pathological consequences of rotavirus infection and its enterotoxin. Am J Physiol Gastrointest Liver Physiol 2001, 281: G303-310.PubMed
146.
Huang H, Schroeder F, Zeng C, Estes MK, Schoer JK, Ball JM: Membrane interactions of a novel viral enterotoxin: rotavirus nonstructural glycoprotein NSP4. Biochemistry 2001, 40: 4169-4180. 10.1021/bi002346sPubMed
147.
Bowman GD, Nodelman IM, Levy O, Lin SL, Tian P, Zamb TJ, Udem SA, Venkataraghavan B, Schutt CE: Crystal structure of the oligomerization domain of NSP4 from rotavirus reveals a core metal-binding site. J Mol Biol 2000, 304: 861-871. 10.1006/jmbi.2000.4250PubMed
148.
Golantsova NE, Gorbunova EE, Mackow ER: Discrete domains within the rotavirus VP5* direct peripheral membrane association and membrane permeability. J Virol 2004, 78: 2037-2044. 10.1128/JVI.78.4.2037-2044.2004PubMedPubMedCentral
149.
Fermin CD, Garry RF: Membrane alterations linked to early interactions of HIV with the cell surface. Virology 1992, 191: 941-946. 10.1016/0042-6822(92)90269-UPubMed
150.
Eisenberg D, Wesson M: The most highly amphiphilic alpha-helices include two amino acid segments in human immunodeficiency virus glycoprotein 41. Biopolymers 1990, 29: 171-177. 10.1002/bip.360290122PubMed
151.
Miller MA, Garry RF, Jaynes JM, Montelaro RC: A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides. AIDS Res Hum Retroviruses 1991, 7: 511-519.PubMed
152.
Kliger Y, Shai Y: A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers. Biochemistry 1997, 36: 5157-5169. 10.1021/bi962935rPubMed
153.
Chen HC, Brown JH, Morell JL, Huang CM: Synthetic magainin analogues with improved antimicrobial activity. FEBS Lett 1988, 236: 462-466. 10.1016/0014-5793(88)80077-2PubMed
154.
Cruciani RA, Barker JL, Durell SR, Raghunathan G, Guy HR, Zasloff M, Stanley EF: Magainin 2, a natural antibiotic from frog skin, forms ion channels in lipid bilayer membranes. Eur J Pharmacol 1992, 226: 287-296. 10.1016/0922-4106(92)90045-WPubMed
155.
Marion D, Zasloff M, Bax A: A two-dimensional NMR study of the antimicrobial peptide magainin 2. FEBS Lett 1988, 227: 21-26. 10.1016/0014-5793(88)81405-4PubMed
156.
Murzyn K, Pasenkiewicz-Gierula M: Construction of a toroidal model for the magainin pore. J Mol Model (Online) 2003, 9: 217-224. 10.1007/s00894-003-0127-z
157.
Yang L, Harroun TA, Weiss TM, Ding L, Huang HW: Barrel-stave model or toroidal model? A case study on melittin pores. Biophys J 2001, 81: 1475-1485.PubMedPubMedCentral
158.
Andreu D, Merrifield RB, Steiner H, Boman HG: N-terminal analogues of cecropin A: synthesis, antibacterial activity, and conformational properties. Biochemistry 1985, 24: 1683-1688. 10.1021/bi00328a017PubMed
159.
Berkowitz BA, Bevins CL, Zasloff MA: Magainins: a new family of membrane-active host defense peptides. Biochem Pharmacol 1990, 39: 625-629. 10.1016/0006-2952(90)90138-BPubMed
160.
Venable RM, Pastor RW, Brooks BR, Carson FW: Theoretically determined three-dimensional structures for amphipathic segments of the HIV-1 gp41 envelope protein. AIDS Res Hum Retroviruses 1989, 5: 7-22.PubMed
161.
Tencza SB, Mietzner TA, Montelaro RC: Calmodulin-binding function of LLP segments from the HIV type 1 transmembrane protein is conserved among natural sequence variants. AIDS Res Hum Retroviruses 1997, 13: 263-269.PubMed
162.
Srinivas SK, Srinivas RV, Anantharamaiah GM, Segrest JP, Compans RW: Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein. J Biol Chem 1992, 267: 7121-7127.PubMed
163.
Phadke SM, Islam K, Deslouches B, Kapoor SA, Beer Stolz D, Watkins SC, Montelaro RC, Pilewski JM, Mietzner TA: Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model. Peptides 2003, 24: 1099-1107. 10.1016/j.peptides.2003.07.001PubMed
164.
Gawrisch K, Han KH, Yang JS, Bergelson LD, Ferretti JA: Interaction of peptide fragment 828–848 of the envelope glycoprotein of human immunodeficiency virus type I with lipid bilayers. Biochemistry 1993, 32: 3112-3118. 10.1021/bi00063a024PubMed
165.
Koenig BW, Bergelson LD, Gawrisch K, Ward J, Ferretti JA: Effect of the conformation of a peptide from gp41 on binding and domain formation in model membranes. Mol Membr Biol 1995, 12: 77-82.PubMed
166.
Fujii G, Horvath S, Woodward S, Eiserling F, Eisenberg D: A molecular model for membrane fusion based on solution studies of an amphiphilic peptide from HIV gp41. Protein Sci 1992, 1: 1454-1464.PubMedPubMedCentral
167.
Phadke SM, Lazarevic V, Bahr CC, Islam K, Stolz DB, Watkins S, Tencza SB, Vogel HJ, Montelaro RC, Mietzner TA: Lentivirus lytic peptide 1 perturbs both outer and inner membranes of Serratia marcescens. Antimicrob Agents Chemother 2002, 46: 2041-2045. 10.1128/AAC.46.6.2041-2045.2002PubMedPubMedCentral
168.
Moreno MR, Giudici M, Villalain J: The membranotropic regions of the endo and ecto domains of HIV gp41 envelope glycoprotein. Biochim Biophys Acta 2006, 1758: 111-123. 10.1016/j.bbamem.2006.01.007PubMed
169.
Miller MA, Cloyd MW, Liebmann J, Rinaldo CR Jr, Islam KR, Wang SZ, Mietzner TA, Montelaro RC: Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology 1993, 196: 89-100. 10.1006/viro.1993.1457PubMed
170.
Gatti PJ, Choi B, Haislip AM, Fermin CD, Garry RF: Inhibition of HIV type 1 production by hygromycin B. AIDS Res Hum Retroviruses 1998, 14: 885-892.PubMed
171.
Haffar OK, Dowbenko DJ, Berman PW: Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein, gp160, in microsomal membranes. J Cell Biol 1988, 107: 1677-1687. 10.1083/jcb.107.5.1677PubMed
172.
Chen SS, Lee SF, Wang CT: Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41. J Virol 2001, 75: 9925-9938. 10.1128/JVI.75.20.9925-9938.2001PubMedPubMedCentral
173.
Haffar OK, Dowbenko DJ, Berman PW: The cytoplasmic tail of HIV-1 gp160 contains regions that associate with cellular membranes. Virology 1991, 180: 439-441. 10.1016/0042-6822(91)90054-FPubMed
174.
Lee SF, Wang CT, Liang JY, Hong SL, Huang CC, Chen SS: Multimerization potential of the cytoplasmic domain of the human immunodeficiency virus type 1 transmembrane glycoprotein gp41. J Biol Chem 2000, 275: 15809-15819. 10.1074/jbc.M000601200PubMed
175.
Chernomordik L, Chanturiya AN, Suss-Toby E, Nora E, Zimmerberg J: An amphipathic peptide from the C-terminal region of the human immunodeficiency virus envelope glycoprotein causes pore formation in membranes. J Virol 1994, 68: 7115-7123.PubMedPubMedCentral
176.
Comardelle AM, Norris CH, Plymale DR, Gatti PJ, Choi B, Fermin CD, Haislip AM, Tencza SB, Mietzner TA, Montelaro RC, Garry RF: A synthetic peptide corresponding to the carboxy terminus of human immunodeficiency virus type 1 transmembrane glycoprotein induces alterations in the ionic permeability of Xenopus laevis oocytes. AIDS Res Hum Retroviruses 1997, 13: 1525-1532.PubMed
177.
Plymale DR, Tang DS, Comardelle AM, Fermin CD, Lewis DE, Garry RF: Both necrosis and apoptosis contribute to HIV-1-induced killing of CD4 cells. Aids 1999, 13: 1827-1839. 10.1097/00002030-199910010-00004PubMed
178.
Plymale DR, Comardelle AM, Fermi CD, Martin DS, Costin JM, Norris CH, Tencza SB, Mietzner TA, Montelaro RC, Garry RF: Concentration-dependent differential induction of necrosis or apoptosis by HIV-1 lytic peptide 1. Peptides 1999, 20: 1275-1283. 10.1016/S0196-9781(99)00132-1PubMed
179.
Miller MA, Mietzner TA, Cloyd MW, Robey WG, Montelaro RC: Identification of a calmodulin-binding and inhibitory peptide domain in the HIV-1 transmembrane glycoprotein. AIDS Res Hum Retroviruses 1993, 9: 1057-1066.PubMed
180.
Tencza SB, Miller MA, Islam K, Mietzner TA, Montelaro RC: Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein. J Virol 1995, 69: 5199-5202.PubMedPubMedCentral
181.
Beary TP, Tencza SB, Mietzner TA, Montelaro RC: Interruption of T-cell signal transduction by lentivirus lytic peptides from HIV-1 transmembrane protein. J Pept Res 1998, 51: 75-79.PubMed
182.
Nokta MA, Hassan MI, Morgan JA, Loesch KA, Pollard RB: Protein kinase C and intracellular free Ca++: relationship to human immunodeficiency virus (HIV)-induced cellular hyporesponsiveness. Proc Soc Exp Biol Med 1994, 207: 284-291.PubMed
183.
Kort JJ: Impairment of excitatory amino acid transport in astroglial cells infected with the human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1998, 14: 1329-1339.PubMed
184.
Bubien JK, Benveniste EN, Benos DJ: HIV-gp120 activates large-conductance apamin-sensitive potassium channels in rat astrocytes. Am J Physiol 1995, 268: C1440-1449.PubMed
185.
Lee SJ, Hu W, Fisher AG, Looney DJ, Kao VF, Mitsuya H, Ratner L, Wong-Staal F: Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity. AIDS Res Hum Retroviruses 1989, 5: 441-449.PubMed
186.
Fisher AG, Ratner L, Mitsuya H, Marselle LM, Harper ME, Broder S, Gallo RC, Wong-Staal F: Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science 1986, 233: 655-659. 10.1126/science.3014663PubMed
187.
Wilk T, Pfeiffer T, Bosch V: Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology 1992, 189: 167-177. 10.1016/0042-6822(92)90692-IPubMed
188.
Gabuzda DH, Lever A, Terwilliger E, Sodroski J: Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 1992, 66: 3306-3315.PubMedPubMedCentral
189.
Yu X, Yuan X, McLane MF, Lee TH, Essex M: Mutations in the cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein impair the incorporation of Env proteins into mature virions. J Virol 1993, 67: 213-221.PubMedPubMedCentral
190.
Freed EO, Martin MA: Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. J Virol 1995, 69: 1984-1989.PubMedPubMedCentral
191.
Iwatani Y, Ueno T, Nishimura A, Zhang X, Hattori T, Ishimoto A, Ito M, Sakai H: Modification of virus infectivity by cytoplasmic tail of HIV-1 TM protein. Virus Res 2001, 74: 75-87. 10.1016/S0168-1702(00)00249-5PubMed
192.
Kim EM, Lee KH, Kim JW: The cytoplasmic domain of HIV-1 gp41 interacts with the carboxyl-terminal region of alpha-catenin. Mol Cells 1999, 9: 281-285.PubMed
193.
Kim JT, Kim EM, Lee KH, Choi JE, Jhun BH, Kim JW: Leucine zipper domain of HIV-1 gp41 interacted specifically with alpha-catenin. Biochem Biophys Res Commun 2002, 291: 1239-1244. 10.1006/bbrc.2002.6583PubMed
194.
Kalia V, Sarkar S, Gupta P, Montelaro RC: Rational site-directed mutations of the LLP-1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope incorporation. J Virol 2003, 77: 3634-3646. 10.1128/JVI.77.6.3634-3646.2003PubMedPubMedCentral
195.
Hirsch VM, Edmondson P, Murphey-Corb M, Arbeille B, Johnson PR, Mullins JI: SIV adaptation to human cells. Nature 1989, 341: 573-574. 10.1038/341573a0PubMed
196.
Kodama T, Wooley DP, Naidu YM, Kestler HW 3rd, Daniel MD, Li Y, Desrosiers RC: Significance of premature stop codons in env of simian immunodeficiency virus. J Virol 1989, 63: 4709-4714.PubMedPubMedCentral
197.
Luciw PA, Shaw KE, Shacklett BL, Marthas ML: Importance of the intracytoplasmic domain of the simian immunodeficiency virus (SIV) envelope glycoprotein for pathogenesis. Virology 1998, 252: 9-16. 10.1006/viro.1998.9467PubMed
198.
Shacklett BL, Weber CJ, Shaw KE, Keddie EM, Gardner MB, Sonigo P, Luciw PA: The intracytoplasmic domain of the Env transmembrane protein is a locus for attenuation of simian immunodeficiency virus SIVmac in rhesus macaques. J Virol 2000, 74: 5836-5844. 10.1128/JVI.74.13.5836-5844.2000PubMedPubMedCentral
199.
Gatti PJ: Role of Membrane Alterations in HIV-1 Infection. In PhD. Tulane University, Department of Microbiology and Immunology; 1998.
200.
Maier H, Budka H, Lassmann H, Pohl P: Vacuolar myelopathy with multinucleated giant cells in the acquired immune deficiency syndrome (AIDS). Light and electron microscopic distribution of human immunodeficiency virus (HIV) antigens. Acta Neuropathol (Berl) 1989, 78: 497-503. 10.1007/BF00687711
201.
Sung JH, Shin SA, Park HK, Montelaro RC, Chong YH: Protective effect of glutathione in HIV-1 lytic peptide 1-induced cell death in human neuronal cells. J Neurovirol 2001, 7: 454-465. 10.1080/135502801753170318PubMed
202.
Tencza SB, Douglass JP, Creighton DJ Jr, Montelaro RC, Mietzner TA: Novel antimicrobial peptides derived from human immunodeficiency virus type 1 and other lentivirus transmembrane proteins. Antimicrob Agents Chemother 1997, 41: 2394-2398.PubMedPubMedCentral
203.
Miceli MC, Moran M, Chung CD, Patel VP, Low T, Zinnanti W: Co-stimulation and counter-stimulation: lipid raft clustering controls TCR signaling and functional outcomes. Semin Immunol 2001, 13: 115-128. 10.1006/smim.2000.0303PubMed
204.
Popik W, Alce TM, Au WC: Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol 2002, 76: 4709-4722. 10.1128/JVI.76.10.4709-4722.2002PubMedPubMedCentral
205.
Bannert N, Schenten D, Craig S, Sodroski J: The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J Virol 2000, 74: 10984-10993. 10.1128/JVI.74.23.10984-10993.2000PubMedPubMedCentral
206.
Ono A, Freed EO: Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001, 98: 13925-13930. 10.1073/pnas.241320298PubMedPubMedCentral
207.
Rousso I, Mixon MB, Chen BK, Kim PS: Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity. Proc Natl Acad Sci USA 2000, 97: 13523-13525. 10.1073/pnas.240459697PubMedPubMedCentral
208.
Fattal E, Nir S, Parente RA, Szoka FC Jr: Pore-forming peptides induce rapid phospholipid flip-flop in membranes. Biochemistry 1994, 33: 6721-6731. 10.1021/bi00187a044PubMed
209.
Wimley WC, White SH: Determining the membrane topology of peptides by fluorescence quenching. Biochemistry 2000, 39: 161-170. 10.1021/bi991836lPubMed
210.
Zhang H, Dornadula G, Pomerantz RJ: Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells. J Virol 1996, 70: 2809-2824.PubMedPubMedCentral
211.
Bour S, Strebel K: The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes Infect 2003, 5: 1029-1039. 10.1016/S1286-4579(03)00191-6PubMed
212.
Shimizu H, Hasebe F, Tsuchie H, Morikawa S, Ushijima H, Kitamura T: Analysis of a human immunodeficiency virus type 1 isolate carrying a truncated transmembrane glycoprotein. Virology 1992, 189: 534-546. 10.1016/0042-6822(92)90577-CPubMed
213.
Shimizu H, Morikawa S, Yamaguchi K, Tsuchie H, Hachimori K, Ushijima H, Kitamura T: Shorter size of transmembrane glycoprotein of an HIV-1 isolate. Aids 1990, 4: 575-576.PubMed
214.
Finkel TH, Banda NK: Indirect mechanisms of HIV pathogenesis: how does HIV kill T cells? Curr Opin Immunol 1994, 6: 605-615. 10.1016/0952-7915(94)90149-XPubMed
215.
Carbonari M, Pesce AM, Cibati M, Modica A, Dell'Anna L, D'Offizi G, Angelici A, Uccini S, Modesti A, Fiorilli M: Death of bystander cells by a novel pathway involving early mitochondrial damage in human immunodeficiency virus-related lymphadenopathy. Blood 1997, 90: 209-216.PubMed
216.
Garry RF: Unexpected similarity between the carboxyl termini of lentivirus and pestivirus envelope glycoproteins. Aids 2003, 17: 276-277. 10.1097/00002030-200301240-00026PubMed
217.
Ciampor F: The ion channels coded by viruses. Acta Microbiol Immunol Hung 2003, 50: 433-442. 10.1556/AMicr.50.2003.4.9PubMed
218.
Griffin SD, Harvey R, Clarke DS, Barclay WS, Harris M, Rowlands DJ: A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. J Gen Virol 2004, 85: 451-461. 10.1099/vir.0.19634-0PubMed
219.
Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278: 1295-1300. 10.1126/science.278.5341.1295PubMed
220.
Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998, 4: 1302-1307. 10.1038/3293PubMed
221.
222.
Metadata
Title
Cytopathic Mechanisms of HIV-1
Author
Joshua M Costin
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2007
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-4-100

Other articles of this Issue 1/2007

Virology Journal 1/2007 Go to the issue

Short report

Cellular apoptosis induced by replication of hepatitis B virus: possible link between viral genotype and clinical outcome

Research

Expression of particulate-form of Japanese encephalitis virus envelope protein in a stably transfected Drosophila cell line

Review

Evolution of temperate pathogens: the bacteriophage/bacteria paradigm

Research

Biochemical characterization of the fidelity of poliovirus RNA-dependent RNA polymerase

Methodology

A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies

Research

Cowpea viruses: Effect of single and mixed infections on symptomatology and virus concentration
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits